Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD318-targeted CAR-T in Pancreatic Cancer
NCT07153289Phase 2Not yet recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
01
Overview
A Phase 2 trial of CD318-specific CAR T cells in pancreatic ductal adenocarcinoma (PDAC), sponsored by University Hospital Tübingen. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
CD318-specific CAR T cells
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07153289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07153289.